Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Oxiracetam | Vinpocetine | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 800-2400 mg/day divided into 2-3 doses | 5-20 mg 2-3 times daily (15-60 mg/day total) |
| Timing | Morning and early afternoon; avoid evening dosing due to mild stimulatory effect. Can be taken with or without food (water-soluble). | With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours). |
| Cycle Duration | Cycles of 8-12 weeks on, 4 weeks off | Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks. |
| Evidence Level | moderate_human | moderate_human |
Modulates cholinergic neurotransmission by preventing scopolamine-induced decreases of acetylcholine in the hippocampus and cortex. Enhances D-aspartate release and modulates AMPA receptor activity. Demonstrates mild stimulatory properties without affecting dopaminergic or serotonergic systems, making it a 'cleaner' cognitive enhancer among racetams.
800-2400 mg/day divided into 2-3 doses
Morning and early afternoon; avoid evening dosing due to mild stimulatory effect. Can be taken with or without food (water-soluble).
Cycles of 8-12 weeks on, 4 weeks off
Semi-synthetic derivative of vincamine (from Vinca minor/periwinkle) that selectively inhibits phosphodiesterase type 1 (PDE1) in cerebral vasculature, increasing cAMP and cGMP levels to promote vasodilation and restore regional cerebral blood flow without significant systemic blood pressure effects. Reduces intracellular calcium in smooth muscle cells and neurons. Inhibits voltage-gated sodium channels, providing neuroprotection against excitotoxicity. Potent anti-inflammatory agent via direct inhibition of IKK, attenuating NF-kB signaling. Downstream CREB and SRF phosphorylation promotes expression of plasticity-related genes.
5-20 mg 2-3 times daily (15-60 mg/day total)
With food (bioavailability increases 60-100% with food). Split into 2-3 doses due to short half-life (~2-3 hours).
Cycles of 8-12 weeks on, 4 weeks off; or ongoing with periodic reassessment. Clinical trials typically run 12-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →